Aureus Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Aureus Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,920	Closed	-$299K	–	179
2018 Q3	$299K	Sell	3,920 -37,898	-91%	-$3.08M	0.04%	152
2018 Q2	$3.21M	Buy	41,818 +3,890	+10%	+$251K	0.44%	43
2018 Q1	$1.93M	Sell	37,928 -2,360	-6%	-$119K	0.29%	51
2017 Q4	$1.87M	Sell	40,288 -18,827	-32%	-$923K	0.29%	51
2017 Q3	$3.15M	Sell	59,115 -6,555	-10%	-$388K	0.5%	43
2017 Q2	$4.08M	Buy	65,670 +14,930	+29%	+$899K	0.69%	38
2017 Q1	$2.93M	Buy	50,740 +45,840	+936%	+$3.49M	0.51%	43
2016 Q4	$345K	Buy	+4,900	New	+$348K	0.07%	102

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Aureus Asset Management's RARE Position: Q4 2018 in Review

Aureus Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2018, closing a stake of 3,920 shares — an estimated $299K sold.

Aureus Asset Management first reported a position in RARE in Q4 2016 and held it in 8 quarters. The position peaked at $4.08M in Q2 2017. 165 funds tracked by Wall St. Rank hold RARE as of Q4 2018.

Aureus Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2018 after selling out during the quarter.
Aureus Asset Management sold 3,920 Ultragenyx Pharmaceutical shares in Q4 2018, an estimated $299K.
Aureus Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2016 and held it in 8 quarters.
Aureus Asset Management's Ultragenyx Pharmaceutical position peaked at $4.08M in Q2 2017.
165 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2018.

Based on Aureus Asset Management's 13F filing for Q4 2018, filed 13 Feb 2019.